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ABSTRACT
CHLAMYDIA;
UNIVERSAL VS SELECTIVE SCREENING
By
Veraeal Y. Glispie
Women, age 20 to 39, attending three family planning clinics within a Michigan health
department, were screened for Chlcmydia trachomatis. A nucleic acid hybridization test
(Gen-Probe) was used to collect cervical specimens for seven consecutive months. A
chlamydia risk assessment form, using Michigan Department of Community Health's
selective screening criteria, was used to determine the client's risk group. A chi-square test
with Yates correction was used for data analysis. The prevalence rates of high and low
risk groups were compared with no significant difference (p = .18). The prevalence rates
were \2.%Vo in Site A; 1.7% in Site B; 1.7% in Site C; and the mean prevalence rate was
3.0%. CDC's 5% prevalence rate, and NCchigan's 1994 local out county, and state
prevalence rates of 7.9% and 5.08% respectively, were used as guidelines for determining
high risk populations. Universal screening was recommended and instituted for Site A, and
selective screening was continued in Sites B and C.
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CHAPTER 1
INTRODUCTION

Chlamydia trachomatis (chlamydia) is the most common bacterial sexually transmitted
disease (STD) in the United States and causes more than four million infections annually
(U.S. Department of Health and Human Services, 1994). Chlamydia has been described as
the silent STD. Approximately 70% of clients with chlamydia are asymptomatic, and the
infection may persist for up to 15 months. Serious complications associated with
chlamydia make annual routine screening, for high risk populations, imperative. The most
frequent complications of untreated chlamydia are pelvic inflammatory disease (FID) and
infertility (Primary Care Update, 1994). An estimated 15% to 40% of women with
untreated chlamydia develop PID. Twenty percent of women with PED become infertile,
18% develop prolonged pelvic pain, and 9% will have one or more ectopic pregnancies
(Kllis, Black, Newhall, Walsh, & Groseclose, 1995).
Several research studies across the country have documented the benefit of universal
chlamydia screening for high risk populations. Although the Michigan Department of
Community Health (MDCH) (formally the Nfichigan Department of Public Health) made
chlamydia a reportable disease in 1992, they have only allocated fimds for selective or high
risk screening. MDCH’s high risk criteria are a) being less than 20 years of age, b) having

a history of STD in the past six months, c) having multiple partners, d) having a partner
with multiple partners, e) having a new partner in the past six months, f) having a
discharge or mucopurulent cervicitis (MPC), and/or g) having a ftiable cervix (MDCH,
1992). Instituting selective screening was a major step in the identification and early
treatment of chlamydia, but the women who are not selected for testing may be at
comparable risk. Universal screening could make the difference between spending an
average of $12 per client for screening and treatment, as opposed to spending hundreds of
dollars on emergency, inpatient, and possibly surgical treatment.
Although MDCH has identified several high risk screening criteria, the client's risk may
not always be accurately determined during an assessment interview. The client may be
reluctant to acknowledge having more than one sex partner, recent treatment for an STD,
or that her partner had more than one sex partner. Situations also occur in which the client
may not be aware that her partner has more than one sex partner or that he had recently
been treated for an STD. Therefore, unless the client is less than 20 years old or
symptomatic, she may not be selected for screening.
Chlamydia testing is done by using culture or nonculture methods to test specimens
obtained from the endocervicai os. Cultures cost $25 to $50, with results returned in
three to seven days. The nonculture test, which is the screening method used by most
clinics, costs $8 to $12, with results available in three to four hours (Drolet, 1992). Due to
the high cost of chlamydia screening, most providers do not routinely offer testing. Failure
of providers to screen routinely for chlamydia leaves asymptomatic women vulnerable to
developing unnecessary complications from this infection. Researchers have suggested

that preventing the complications of chlamydia could save states millions of health care
dollars in outpatient and inpatient care for treatment of PID, ectopic pregnancies, or other
complications. First year savings were estimated at six million dollars with five year
savings reaching more than $60 million (U.S. Public Health Service, 1991).
In the three-year period of 1992-1994, two family planning clinics in an urban health
department selectively screened 1,077 females using MDCH protocol. Of those 1,077
female clients, 16 to 39 years of age, 118 tested positive for chlamydia. This represented a
16% prevalence rate at Site A, 9.7% at Site B and a mean prevalence rate of 11% (Wayne
County Department of Health, 1994). The Centers for Disease Control (CDC) (1993)
rates any prevalence > 5% as indicative of a high risk population. These retrospective data
obtained fi'om the local health department did not include data on the low risk population,
and specific descriptive data were not available. The data did, however, provide good
background information and were the basis for this study.
The National Health Promotion and Disease Prevention Objectives for the Healthy
People 2000 initiative include a focus on reducing the spread of STD's. Effective methods
of early identification and treatment of chlamydia were among those objectives (U.S.
Public Services, 1991). After MDCH made chlamydia a reportable disease in 1992, it
became imperative that all health care professionals serving sexually active clients take
chlamydia seriously. The Michigan Department of Community Health (1994) reported 288
cases of chlamydia in 1992, 4,783 cases in 1993, and 17,688 cases in 1994. It is not clear
if the previous figures represent a true increased prevalence or if t h ^ reflect increased
screening and reporting practices in NCchigan. Nevertheless, rates of 9.7% and 16% in

these family planning clinics were above the mean prevalence rate of 5.1% for Michigan
family planning clinics in 1994 (MDCH, 1995). In order to evaluate the effectiveness of
the present screening criteria, this study compared the prevalence rates of the low risk
groups to those of the high risk groups in three health department family planning clinics.
It used the prevalence rates found in each risk group to determine whether universal
screening or selective screening protocols would be more appropriate for use in these
clinics.
The purpose of this study was to determine if the selective screening protocol,
currently used by the urban health department, was adequate for screening their clinic
populations or if universal screening would be preferable. Despite multiple studies on high
risk criteria for chlamydia, researchers remain unable to establish reliable positive
predictors for this infection and recommend universal chlamydia screening for high risk
populations (Phillips, Aronson, Taylor, & Safran, 1987). CDC, also, recommends sentinel
or periodic universal screening to monitor the prevalence of chlamydia in target
populations.

CHAPTER 2
LITERATURE AND THEORY

Chlamydial infections have become the most common sexually transmitted disease in
the United States. Although the cost of early treatment is minimal, the cost of testing has
prevented widespread screening (Weinstock et al., 1992). In the 1980's, multiple studies
were conducted to determine risk factors that would serve as positive predictors for
chlamydia, and to determine which nonculture test shows the highest specificity and
sensitivity for this bacterial infection. The higher the specificity of the nonculture test the
more likely a negative result indicates the infection is not present; thus, the test has a
higher rate of true negatives and a lower rate of false positives. The higher the sensitivity
of the nonculture test the more likely a positive result indicates the infection is present;
thus the test has a higher rate of true positives and a lower rate of false negatives. In
addition, reliable positive predictors would make selective screening an alternative to the
higher cost of universal screening. In spite of the many studies done on chlamydia,
researchers have been unable to establish highly reliable predictors for high risk
populations. Thus far, the nmjor savings have been by the use of nonculture chlamydia
testing for mass screenings, reserving the more costly culture test for cases with legal
implications.

The literature review showed three basic types of studies. These were universal
screenings, selective screening, and cost benefit studies. Universal screening studies
focused on the benefit of screening all clients in high risk populations. Selective screening
studies focused on screening only clients meeting predetermined high risk criteria as a cost
reduction measure. Cost benefit studies compared the direct and indirect cost of screening
and treatment when needed. The direct cost related to the mtpense of screening and
treatment of uncomplicated cases, and the indirect cost related to complications and
treatment for untreated chlamydial infections. Key variables, which included the lower end
of the screening test's sensitivity, the direct and indirect cost of testing and treatment, and
the population's prevalence rate for chlamydia, were analyzed to determine at what
prevalence rate the cost of universal screening would outweigh the cost of treating
complications from undetected cases. Betty Neuman’s Systems Theory was used as a
basis for examining risk factors and prevalence rates of chlamydia. Her concepts of
“Primary and Secondary Prevention as Intervention” (Neuman, 1995) are discussed as
they relate to the importance of screening for chlamydia.

UmYgsal^grgeniog
Dr. Russell Phillips (1987), from Harvard Medical School, along with several other
researchers recommended routine or universal screening in populations with a prevalence
rate above 6% to 7%. Universal screening was recommended because a) 60% to 80% of
clients who had chlamydial infections are asymptomatic, b) there is a high probability of
obtaining inaccurate histories relating to the client's sexual partner(s), and c) highly reliable
risk factors have not been established (Woolard, Canp, Larson, & Hudson, 1989). The

relationship of prevalence to screening protocols are discussed in conjunction with cost
benefit analysis. Several universal screening studies were done in urban family planning
and STD clinics. Included in this literature review were studies conducted in Midwestern
USA, Ohio, California, Virginia, Colorado, New York, and Canada.
In the early 1980's, a chlamydia study was conducted by Woolard et al. (1989) at a
NCdwestem university campus (Table 1). The result of this study showed a prevalence rate
of 12.6%, using Abbott's Chlamydiazyme nonculture test. CDC reports nonculture
tests such as Chlamydiazyme to have a sensitivity of 67% to 95% and a specificity o f 97%
to 99%. Of the 419 females who were screened, 53 of them tested positive for chlamydia.
Limitations of this study were cited as having a high possibility of a) false-positive results
with the use of Chlamydiazyme nonculture test in low prevalence populations; and b)
inaccurate historical data reported by the client, related to her own or her partner(s)
history of past STD's, and the number of partners the client or her partner(s) have had in
the past year. This study concluded that due to the high incidence of asymptomatic women
found to have chlamydia, routine testing is strongly recommended in most college based
family planning clinics.
A study conducted at Columbus Health Department screened 60,000 to 70,000
females annually for three years. Reports fi’om this study showed a decrease in prevalence
fi’om 8.8% in 1985, to 5% in 1988 (Johnson, 1992). Although a nonculture test was used
in this study, the type of test, sensitivity, and specificity were not reported. Johnson states
that this study and others were limited by unsatisfactory collection of endocervicai cells

Table 1.

Chlamydia: Univsrsal Sçregning Studies
DATE OF
STUDY/
AUTHOR

LOCATION

TEST

POS

RATE

TEST USED

12.6%

Chlamydiazyme
(Abbott)

1980's
Woolard
et al. (1989)

Midwestern
University

419

53

1985-88
Johnson, M.
(1992)

Columbus
Health Dept.

60,00070,000
x3yrs

ukn

1987-88
Weinstock
et al. (1992)

San Francisco

1,348

124

1987-88
Johnson, B.
et al. (1990)

Virginia
Commonweal
th University

1,458

133

SEN

SPEC

CONCLUSIONS

•67%
to
95%

•97%
to
99%

High % of asymptomatic clients &
inaccurate hx's limits predictability for
chlamydia. Routine (universal) screening
was recommended for college women.

unspecified
nonculture

•67%
to
95%

•97%
to
99%

Widespread universal screening decreased
the prevalence rate by 43% in 3.5 yrs.
Replication of this project, especially for
teen & Black populations recommended.

9.2%

MicroTrak
DFA

**
61%

98%^

Recommended universal screening in high
risk populations and selective screening for
use in low risk populations.

9%

MicroTrak
DFA

•61%
to
90%

98%^

No current selective screening model yet
proven to be reliable.Verification of this or
other study model needed before selective
screening is eflective for use in high risk
populations.

8.8%
in 1985
to 5%
in 1988

Note. ^Manufacturer's or CDC's data ** Data reported in study Pos = Positive Sen = Sensitivity Spec = Specificity DFA = direct
fluorescent antibody ELA = enzyme immunoassay

(table 1 continues)

Table 1. (continued)
Chlamydia: Universal Screening Studies
Date of
Study
AUTHOR

LOCATION

TEST

POS

RATE

TEST USED

2,437
males females

419

17%

MicroTrak
DFA

**
90%

**
98%

20.5% positives identified via contacttracing, 59.7% via routine screening, &
19.8% presented to clinic with
symptoms.
Increased reporting would facilitate
contact follow-up

SEN

SPEC

CONCLUSIONS

1988
Zimmer
man et al.
(1990)

Colorado
Springs

1988
Holmes
etal.
(1993)

New York
City
Correctional
Institution

101

27

27%

Unspecified
cell culture

**
80%

*
nearly
100%

Combination of 3 high risk indicators
only identified 70% of women positive
for chlamydia. Recommend routine
screening for all inmates on admission.

1980-81
Embil &
Pereira
(1985)

Halifax,
Canada

355

29

8.2%

Unspecified
cell culture

*
80%

*
nearly
100%

All clients screened were asymptomatic.
Chlamydia was much more prevalent in
women under 25 years. Chlamydia was
also higher in women with multiple
partners.

1989-90
Sellers
et al.
(1992)

McMasters
University
Ontario

1,002

70

7%

Chlamydiazyme
ElA
(Abbott)

**
78.6%

*97%
to
99%

Use of 4-5 predictors was effective for
screening low prevalence populations.
Saving gained in reduced cost of
selective screening are lost with the
increased cost of treatment for missed
cases in high prevalence populations.

necessary for proper analysis. An average of 15% to 30% of unsatisfactory specimens may
be found with widespread testing. To reduce this problem, the Columbus project
sponsored in-service training to participating providers. Johnson concluded that the
widespread universal screening done in the Columbus Health Department decreased the
prevalence rate by 43% in about three years. Therefore, he recommends the replication of
this project wherever possible, especially in high risk, teen, and predominately Black
populations.
During a 1987-1988 study in San Francisco, Weinstock, Bolan, Kohn, Balladares,
Back, and Oliva (1992) screened 1,348 females for chlamydia. With 124 women testing
positive, the prevalence rate was 9.2%. A direct fluorescent antibody test, with a
sensitivity of 61% as compared to 99% with cultures, was reported as a limitation of this
study. Although no additional data were presented, the use of cytobrushes to collect
endocervicai specimens was felt to improve the sensitivity of the nonculture test.
Weinstock et al. felt that due to the low sensitivity of the nonculture test, universal rather
then selective screening should be used in high risk populations to increase the numbers
screened, thus increasing the number of positive cases detected.
In a study conducted at Virginia Commonwealth University, 1,458 females were
screened, and 133 tested positive for a prevalence rate of 9% (Johnson, Poses, Fortner,
Meier, & Dalton, 1990). A direct fluorescent antibody (DFA) nonculture test was also
used in this study, but no sensitivity or specificity data were reported. Since the cost of
universal screening was a major concern for the Virginia Commonwealth University
Clinic, a selective screening model designed to identify high, moderate, and low risk
10

clients was developed. The researchers admit that models so far have not been reliable but
feel that one will be developed in the foreseeable future.
In Colorado Springs, a study o f 2,437 males and females reported 419 positive tests
and a prevalence rate of 17% for chlamydia (Zimmerman, Potterat, Dukes, Muth,
Zimmerman, Fogle, & Pratt, 1990). In this study the NCcroTrak DFA's sensitivity was
reported as 90%. Contact-tracing was responsible for identifying 20.5% of the positive
chlamydia cases, 59.7% were identified by routine screening, and only 19.8% of clients
presented to the clinic with symptoms. Zimmerman et al. advised that increased reporting
of chlamydia cases to public health ofBcers would facilitate contact follow-up.
A 1988 study, conducted at New York City's Rikers Island Correctional Institution,
found that of 101 females screened, 27 of them tested positive, with a prevalence rate of
27%. An unspecified cell culture with a sensitivity of 80% was used in this study. Since
only 70% of the infected inmate population would have been identified using selective
screening criteria, testing or offering presumptive treatment to all new female inmates was
suggested (Holmes, Safyer, Bickell, Vermund, Hanf^ & Phillips, 1993).
Canadian studies have shown similar findings During 1980 and 1981 in Halifax, 355
females were screened, and 29 of the women tested positive for chlamydia. The
prevalence rate was 8.2%. Chlamydia was found to be more prevalent in women less than
25 years old and higher in women with multiple partners (Embil & Pereira, 1985).
In a study conducted at the McMaster University Student Clinic in Ontario, 70, out of
1,002 females screened, tested positive, thus having a prevalence rate of 7%. Abbott's
Chlamydiazyme enzyme immunoassay (ELA) nonculture test was used and reported to
11

have a sensitivity of 78.6% in that study. Canadian researchers agreed that in low
prevalence settings, selective screening offered an efScient strategy compared with
universal screening. Whereas in high prevalence settings, the increased costs incurred by
treating the sequelae among missed cases reduced any savings associated with a selective
screening program. The opportunity cost principle recognizes the existence of other costeffective services that compete for women’s health resources. It also recognizes that the
limited resources of health care systems were the main forces propelling efforts to
efficiently screen women for this disease (Sellers et al., 1992).
Universal screening studies in these urban areas all showed that despite the individual's
risk factors, when nonculture tests were used for routine screening, the prevalence rates
ranged fi’om 5% to 27% with a mode rate of 8% to 9%. Several high risk indicators for
chlamydia were identified in all o f the studies; but no single indicator was consistently
found to be a determinant for the presence of the chlamydial infection. All studies were
limited by the use of convenience samples as opposed to random sampling. Using only
clients who came into the clinics for services may not have produced an accurate sample
of the target population at large.
Selective Screening
Multiple selective screening studies have been conducted to identify specific high risk
indicators of chlamydia. Finding one or more reliable indicators would allow providers to
screen only those clients at risk for the infection, thereby saving the cost of routinely
screening all clients (Addis, Vaughn, Holzhueter, Bakken, & Davis, 1987). Researchers
looked at several high risk factors identified in universal screening studies and used them
12

to develop selective screening protocols. Although both culture and nonculture tests were
used in various studies for purposes of comparison, this literature review primarily focused
on prevalences obtained using nonculture tests (Table 2).
Between 1980-1982, a study was conducted at a University of California / Los
Angeles (UCLA) Student Health Center. Six hundred and thirty-eight females, with some
predetermined high risk factors, were selectively screened for chlamydia. Using the Eagle
cell culture, 42 students tested positive, and the prevalence rate was determined to be
6.6%. Risk factors for those testing positive included a mean age of 23.5, multiple
partners, a partner with a recent history of urethritis, and/or the use of contraceptives. No
associations were found between a positive chlamydia test and a history of testing positive
for sexually transmitted diseases including gonorrhea, chlamydia, syphilis, or genital
herpes. Nor was there any association with Trichomonas or GardnerelUr, dyspareunia;
abnormal vaginal discharge, burning, or odor, dysuria; or cervicitis on examination by
clinicians. Although there are few reliable clinical markers that would identify positive
chlamydia cases, clients with multiple partners and partners with nongonococcal urethritis
(NGU) were the most common indicators in this UCLA clinic population (Weismeier,
Lovett, & Forsythe, 1984). No specific recommendations were made regarding universal
versus selective screening in this study, but the previous statement regarding multiple
partners and NGU gives some direction in support of selective screening.

13

Table 2.
Chlamydia: Selective Screening Studies
UCLA
Student Health
Center,
1980-82
(Wiesmeier
et al., 1984)

Seattle Public
Health Clinic,
(unspecified year)
(Handsfield,
et al., 1986)

Wisconsin
F.P. Clinic, 1985
(Addiss et al.,
1987)

Milwaukee
Community &
Urban Health
Center, 1986
(Addiss et al.,
1990)

New York State
Public Health
Clinics,
1985-86
(Han et al., 1993)

San Diego
County Public
Health
Centers,
1989-93
(CDC, 1994)

# Tested &
Age Range

638
Unspecified

1,059
> 14yrs

335
14-37 yrs

751
13-49 yrs

1,531
16-27 yrs

11,044
n/a

Prevalence
Rate

6.6%
(42)

9.3%
(98)

10.7%
(36)

12.4%
(93)

13.6%
(208)

10.0% in
1989 to
1.9% in 1993

Test(s) used

Eagle Culture

MicroTrak
DFA

DFA
Chlamydiazyme
ElA

MicroTrak DFA
&
ElA

MicroTrak-DFA
Chlamydiazyme ElA by Abbott
(A-EIA)

♦♦DFA - 77.4%
♦♦A-EIA - 83.9%

♦DFA - 92%
♦A-EIA 83.9%

Sensitivity

n/a

♦DFA 92%

♦♦89%-90

Specificity

n/a

♦DFA 98%

♦♦97%-98%

MicroTrak EIA(M-EIA)
3/91-3/93
♦M-EIA 93%

♦♦DFA - 96.8%
♦ DFA - 98%
♦M-EIA 99%
♦♦A-ElA-97%
♦A-EIA 97%
Note, n/a = not assessed in this study NR = no relationship found in this study ♦ Manufacturers or CDC data ♦♦data reported in t lis study
♦•^Screening criteria recommended at conclusion of this study Direct fluorescent antibody (DFA) Enzyme immunoassay (ElA)
Nongonococcal urethritis (NGU)
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Table 2. (continued)
Chlamydia: Selective Screening Studies

Age

Recent new
partner
Hxof >1 sex
partners or partner
with>l partner
in the past
2 months to 1 yr

(Wiesmeier
etal., 1984)
***
mean age 23.5

n/a

30% •**

(Handsfield
etal., 1986)

(Addiss et al.,
1987)

(Addiss et al.,
1990)

<24 yrs***
mean age 21.8
12.4%

15% <20 yrs***
16%<20
6.7% >20

<20 yrs 19.65
>20 yrs 9.5

17.3%***
< 2 months

17.5%***

***23.1%
< 3 months

n/a

***
< 3 months

8.3% 0-1 partners
*** >2 partners
past two months
15.6%

29.2%***

*** >1 partner
<3 months
25.3%
>1 pastyr
21.6%

*** >1 partner
<6 months
12.7%
none or one
10.5%

***
> partner
< 3 months

(Han et al., 1993)

<20 yrs 17.9%
12.3%>20yrs
mean age 21

(CDC, 1994)
***
<20 yrs 8.4%

Partner with hx of
NGU < 30 days

***33%

n/a

100% ***

***28.1%

n/a

n/a

Nonbarrier
methods

n/a

***
25.8%

n/a

none, rhythm or
withdrawal 13.9%

6%

AAA

Hx of GC

NR

NR

LR

***Partncr - GC
<30 days 40%

NR

n/a

Current GC

0.8%

1.2%

0.3%

***36.4%

NR

n/a

MPC

NR

23.3%***

***40%

***

mucoid 11.3%
purulent 25.8%
15

***
17.7%

***

(tabic 2 continues)

Table 2 (continued)
Chlamydia: Selective Screening Studies
(Wiesmeier
etal., 1984)

(Handsfield,
etal., 1986)

(Addiss et al.,
1987)

(Addiss et al.,
1990)

(Han et al., 1993)

(CDC, 1994)

Friable cervix

n/a

19%***

***26.5%

***20.9%

n/a

n/a

Symptomatic

6.6%

8.7%

11.3%

n/a

n/a

Inflammation on
Pap smear

n/a

n/a
Inflammatory
changes on
current Pap
42.9% last Pap
28.2%

> 5 lymphocytes
on 400x field
22.0%
<5 = 11.5%
S+-4+ PMN
29.9%
0.2+ 10.= 9%

***16.9%
«««
25% pos in one
clinic
13%negin same
clinic

Selective screening
is useful in
directing limited
testing funds to
those most likely
to be infected.

Recommends
universal
screening for
all initial
exams and
selective
screening for
annual and
other visits

Conclusions

Few reliable clinical
markers that could
identified positive
cases. Multiple
partners & partners
with NGU were the
most common
indicators in this
university
population

No single risk
factor identified.
Which supports
other studies
recommendations
for universal
screening. Selective
screening
recommended for
women with > 2
risk factors*** as a
cost-effective
means for early
detection of
chlamydia

No single
symptom or
cluster of
symptoms were
reliable
predictors of a
positive DFA.
Major finding:
client's reason
for visit not
predictive of
positive test.
Recommend all
clients be
assessed for risk.
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No one variable
had sufficient
predictive value
for use as only
criterion to
selectively screen
this population for
chlamydia.
Proposed criteria
would screen 43%
of clients &
identify 71% of
infections.

n/a

A Seattle public health clinic universally screened 1,059 females to determine high risk
fectors. Using the MicroTrak DFA nonculture test, 98 clients tested positive for a
prevalence rate of 9.3%. Significant characteristics of those testing positive included
a) being < 24 years of age, b) two or more s&oial partners in the past two months,
c) a recent new partner, d) an abnormal vaginal discharge, e) a mucopurulent cervicitis,
f) a fiiable cervix, and g) cervical ectopy (ectropion). Nonsignificant predictor
characteristics for chlamydia in this study included race, age at the onset of sexual
intercourse, recent history of STD’s, complaints of vaginal itching or irritation, urinary
tract symptoms, lower abdominal pain, or pain with sex. The study concluded that no
single risk factor was identified as a positive predictor for chlamydia, which supports other
studies' recommendations for universal screening. However, as a cost-saving measure,
Handsfield, Jasman, Roberts, Hanson, Kothenbeutel, and Stamm (1986) recommended
selective screening for women with two or more of the risk factors identified in this study.
In a study conducted at four Wisconsin family planning clinics, 335 females were
selectively screened. DFA and Chlamydiazyme ELA nonculture tests, with a sensitivity of
89% to 90% and a specificity of 97% to 98% respectively, resulted in 36 positive tests and
a prevalence of 10.7%. Risk factors similar to those used in previous studies were used to
determine the predictive criteria for this study. The major correlated factors included
having a new sexual partner, a partner with urethritis, a partner with more than one
partner, a fiiable cervbc, a mucopurulent discharge, or being less than 20 years old. A
likely relationship between a current history of gonorrhea and a current positive
chlamydial infection was found in this study. It also noted that younger women were more
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prone to cervical ectropion than older women. Cervical ectropion is a condition in which
more columnar epithelial cells are exposed and thus makes women < 24 years old more
susceptible to chlamydia (Addiss, Vaughn, Holzhueter, Bakken, & Davis, 1987) The
client's reason for visiting the clinic was not found to be predictive of chlamydia. Nor was
there any relationship found between chlamydia and the client's race, educational level,
martial status, history of STD's (other than gonorrhea^), genitourinary related symptoms,
or the use of oral contraceptive pills (OCP's). No single symptom or cluster of symptoms
was found to be a reliable predictor of chlamydia. Addiss et al., however, recommended
high risk selective screening, that would detect 89% of clients with chlamydia by testing
only 58% of the clinic population.
In 1986, two Nfilwaukee, Wisconsin family planning clinics conducted a study.
Universal screening was done on 751 females who were assessed as having similar high
risk factors. Ninety-three of them tested positive, for a prevalence of 12.4% using the
DFA and 13.1% using the ELA The DFA’s had a sensitivity of 77.4%, resulting in 22.6%
false negatives; and a specificity of 96.8%, resulting in 3.2% Alse positives and a
predictive value positive (PVP) of 77%. EIA had a sensitivity of 83.9% (thus a false
negative rate of 16.1%), a specificity of 97% (thus a false positive rate of 3%), and a PVP
of 80%. When high risk criteria were used including a) cervicitis; b) positive GC; c)
partner with NGU, epididymitis, or GC within the past 30 days; and d) more than one
sexual partner, or a new partner within the past 3 months, 43% of the 751 clients were
identified as high risk and tested. This resulted in identifying 71% of clients actually having
a positive chlamydia test. Although Addiss, Vaughn, Golubjatnikov, Pfister, Kurtycz, and
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Davis (1990) recognize selective screening as an effective cost saving alternative, they still
recommend universal screening for adolescents and women seen in high risk areas, if
resources are available.
A study conducted in ten clinics outside New York City screened 1,531 females for
chlamydia. Positive tests were reported for 208 of those tested, yielding an overall
prevalence rate of 13.6% (Han, Morse, Lawrence, Murphy, & Hipp, 1993). A prevalence
of 17% was reported for the eight high risk family planning and STD clinics. In the two
low risk private and college clinics, the prevalence rate was 5.6%. Six high risk indicators
observed in this study were clients less than 20 years old, multiple partners, the use of
OCP’s, MPC, inflammation on Pap smear, and symptomatic reason for their clinic visit.
No relationship with race or history of other STDs was found. The authors of this study
believed that the relationship between use of OCP's and chlamydia was explained by the
tendency of estrogen and progesterone to foster the growth of chlamydia and an increase
of ectropion in women using OCP's. This study also discussed the possibility that the use
of antibiotics, vaginal creams, and douches may have masked the presence o f chlamydia,
thereby increasing the chances of obtaining false negative results. Han et al. state that
selective screening is useful in directing the limited testing funds to clients most likely to
be infected.
A five year study, conducted in six San Diego County public health centers, found that
after screening 11,044 females during routine initial or annual visits, the prevalence
decreased fi’om 10.0% in 1989, to 1.9% in 1993. Ninety-one percent of those screened
were asymptomatic. At the start of the study, fi'om March 1989 through February 1991,
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the Ortho Diagnostic Systems enzyme-linked immunoabsorbent assay (ELISA) test was
used for screening. Although no reason was documented for the change in collection and
testing methods, in March of 1991 the MicroTrak EIA was used to complete the testing.
No sensitivity or specificity data were documented in this report. The high risk indicators
in this study were being of the Black race and being less than 20 years old. Other
indicators included having multiple partners or a new partner in the past three months,
using a non barrier method of contraception, and having mucopurulent cervicitis. The
results of this study led to the implementation of policy by the California OflBce of Family
Planning in August 1993, which requires universal screening on all initial examinations and
selective screening for annual and other clinic visits (CDC, 1994).
Selective screening studies have consistently identified several high risk factors that
were predictive of a chlamydial infection. The one factor that consistently showed the
highest risk was women less than 20 years old. Other factors associated with high risk
were having multiple partners or a new partner in the past three months, a partner with
multiple partners, single status, abnormal vaginal discharge, cervicitis, failure to use
condoms, a recent history of gonorrhea, and symptoms of an urinary tract infection.
However, no single fiictor or group of risk factors were shown to be highly reliable
predictors in replicated studies. As a result, most clinics adopt a set of high risk
characteristics identified in their study of choice and accept the selective screening
predictive value "positive" of 77%, to save the cost of universally screening all clients.
The weakness of this strategy is that 23% of clients with chlamydia are missed, and many
go on to have long term complications from an untreated infection.
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Cost Versus Benefit
Cost benefit studies were done primarily to determine at what prevalence rate the cost
of selective or universal screening pays for itself. Although the cost of screening in dollars
is an inescapable factor, providers should not ignore the serious consequences this STD
can inflict on a very vulnerable population. Statistics show that within five years of an
infection, many clients with untreated chlamydia suffer fi'om PID resulting in chronic
pelvic pain (due to adhesions), infertility, and/or complications of pregnancy (Hillis et al.,
1995). These facts support the Phillips et al. (1987) study which recommends routine
screening in high risk populations, defined by CDC as a prevalence > 5%.
A 1984 study conducted in Boston determined the break-even prevalence rate for
nonculture tests to be 7% and 14% for culture tests, when direct and indirect costs of
treatment were considered (Table 3). The cost of using nonculture tests such as the DFA
and EIA rapid test was $15, and treatment with doxycycline was $2. The sensitivity and
specificity for DFA and EIA reported in this study were 80% and 98% respectively. Only
the cost of the test and the medications were considered because the other costs would
normally be included in the cost of a routine family planning visit. Phillips, Aronson,
Taylor, and Safi'an (1987) determined that the cost of screening and treatment will pay for
itself if the prevalence rate is greater than 7%.
Neddleman and Jones (1988) evaluated the prevalence rate of a college population to
be 7.9%, and the cost-eflfectiveness prevalence rate to be 7.94%. A direct antigen
nonculture test, with a sensitivity of 53% and a specificity of 96%, was used in this study.
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Tables.
Chlamydia: Cost Versus Benefit Studies
Location
Dale
Type clinic
Number
screened

Break -even
prevalence
rate

Rate
Pos

Test
used

7%
nonculture
14% culture

7%

DFA
EIA

7.9%

Direct
Antigen

53%**

96%**

Micro
Trak

90%**

98%**

Phillips et al.
(1987)

Boston
1984

Neddleman
& Jones
(1988)

1985-6
college clinic
434

7.94%

Trachtenberg,
et al.
(1988)

California
1986
F.P. clinics
400,000
annually

(as low as
1.84% to
2.59%)
Baseline
5.98%

9.8%
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Sen

80%**
80%**

Spec

98%**
98%**

Cost of test
&
Treatment

Conclusions

Nonculture
test - $15
Meds $2

Only the cost of test and
meds were considered.
Other costs are charged
to a routine F.P. visit.
Thus if prevalence rate
>7, screening & tx pays
for itself

$12
Meds $1.09

The use of a low-cost
direct antigen test, more
effective than not
testing and or treating

$6.75 test
$2 - meds
$16- return visit
$20 -visit & tx
for partner

Universal screening cost
effective if prevalence
>6%

(table 3 continued)

Table 3. (continued)
Chlamydia: Cost Versus Benefit Studies
Location
Date
Type clinic
Number
screened

Break even
prevalence
rate

Rate
Pos

Test
used

7.7%

Chlamy
diazyme
EIA

79%**

97%**

DFA
LCR

75%**
95%**

*97%
to 99%

Humphreys,
et al.
(1991)

Colorado
1988
F.P. clinics
11,793

2%

Marrazzo
(1994)

Region X
1990
F.P. clinic
11,141

1.8%
1.9% to
3.5%

6.6%

Sen

Spec

Cost of test
&
Treatment

Conclusions

Not screening
$0.00
Selective
Screening
$82,500.00
Universal
Screening
$203,500

Universal screening
would decrease
morbidity for clients
with chlamydia &
significantly reduce
health care cost

$5
$10-$25

Require 56% be tested
78% detected.
Selective screening is
cost effective in low
prevalence populations
Note Pos = positive Sen = sensitivity Spec = specificity DFA = direct fluorescent antibody EIA = enzyme immunoassay
LCR = ligase chain reaction
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The cost of the direct antigen test was $ 12, and the cost o f the medication was $ 1.09.
The authors concluded that the use of a low cost direct antigen test was more effective
than not testing or treating clients for chlamydia.
California's state-hmded family planning clinics, with a reported prevalence rate of
9.8%, were studied in 1986 using a decision tree. The purpose was to determine the total
cost of universally screening or not screening the estimated 400,000 women, annually seen
in California's state family planning clinics. The total cost of universal screening was
$7,307,717 (Table 4). They compared this with the cost of $20,347,401 required to pay
for hospitalization, surgical procedures, and medications for treatment of PID, ectopic
pregnancies, infertility, and neonatal pneumonia and conjunctivitis, when no chlamydia
screening was done. Break-even prevalence rates were determined to be as low as 1.84%
to 2.59% using the MicroTrak nonculture test, with a sensitivity of 90% and specificity of
98%. The MicroTrak test cost $6.75, medication per person was $2, the cost of a return
client visit was estimated to be $16, and the cost of a contact partner visit and treatment
was $20. As a result, universal screening was determined to be cost efifective if the
prevalence rate was greater than 6% (Trachtenberg, Washington, & Halldorson, 1988).
A 1988 study conducted in 22 Colorado family planning clinics found that of 11,793
females tested 913 tested positive, which calculated the prevalence rate to be 7.7%. The
total cost of not screening for chlamydia in this study was $0 for direct cost and
$1,370,000 for the indirect cost (Table 5). Indirect cost included outpatient and inpatient
treatment related to PID, ectopic pregnancy, tubal infertility, epididymitis, and neonatal
pneumonia and conjimctivitis. Although the selective screening criteria were not specified,
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Table 4.
Chlamydia Testing and Treatment: Cost Under EachDecision OotioiLat California Fanulv
Planning Clinics
Screened ($)
Testing
Treatment
Complications

Unscreened ($)

$2,700,000

$0

1,529,856

0

127,488

0

Women with PID
Outpatient Rx

255,780

1,764,000

1,270,928

8,765,022

255,780

1,764,000

Epididymitis, outpatient

11,368

78,400

Epididymitis, inpatient

40,947

282,391

Ectopic pregnancy

327,342

2,257,528

Tubal infertility

746,025

5,145,000

39,078

269,500

3,126

21,560

$7,307,717

$20,347,401

Hospitalization
Surgery

In births to infected women;
Neonatal pneumonia
Neonatal conjunctivitis
TOTAL COSTS (1986 Dollars)

Source: Trachtenberg et al. (1988). A cost-based decision analysis for chlamydia screening
in California family planning clinics. Obstetrics and Gvnecologv. 71.104.
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Table 5.
Cost Decision Analysis for Chlamydia trachomatis Screening in Colorado Family Planning
Clinks.
Total Health
Cost Dollar
(Indirect Cost)

Total Cost
Per
Protocol

$0

$1,370,000

$1,370,000

Selective Screening

$82,500

$1,120,000

$1,202,500

Universal Screening

$203,500

$607,000

$810,500

Scenario
No Chlamydia Screening

Screening Cost
Dollars
(Direct Cost)

Source: Humphreys et al. (1991). Cost-benefit analysis of selective screening criteria for

Chlcanydia trachomatis in women attending Colorado family planning clinics. Sexually
Transmitted Diseases. 19. 51.

the direct cost was $82,500, the indirect cost of selective screening was $1,120,00 for a
total cost of $1,202,500. This figure was based on the a) cost of testing using the
Chlamydiazyme EIA nonculture test with a sensitivity of 79% and a specificity of 97%,
b) treatment as needed for those selectively screened, and c) the cost of treating
complications in clients not screened who were subsequently found to have chlamydia.
Universal screening was estimated at $203,500 for direct cost and $607,000 for indirect
cost, with a total of only $810,500. This low cost was attributed to the cost of routine
testing and early treatment of chlamydia, which eliminated or reduced the occurrence and
cost o f treating complications. This study was based on the application of the
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Trachtenberg decision model, used in California in 1986, to determine the total cost of
screening versus the cost of not screening, using a break-even point of a 2% prevalence
rate. Although state and federal funds only support selective screening at this time,
Humphreys, Hennebeny, Rickard, and Beebe (1991) noted that universal screening would
decrease the morbidity for clients with chlamydia and significantly reduce health care cost.
Region X conducted a study in 1990. Their 6mily planning clinics, located in
Washington, Oregon, Alaska, and Idaho, selectively screened 11,141 females. Seven
hundred-thirty-five subjects tested positive, for a prevalence of 6.6%. They found that
selective screening would require testing 56% of the &mily planning clients, and that 78%
of chlamydia infections would be detected. Cost effectiveness was based on the prevalence
of chlamydia in the target population, the sensitivity of the screening criteria, the
sensitivity of the diagnostic test, and the cost of the diagnostic test used. It was
determined that, in a predominantly asymptomatic family planning population, selective
screening is cost-effective if the prevalence rate is low. T h ^ defined low in this study to
be less than 1.8%, using the DFA which had a sensitivity of 75% and cost $5 per test.
However, 1.9% to 3.5% was the breaking point when the ligase chain reaction (LCR) test
was used, which had a sensitivity of 95% and cost $10 to $25 (Marrazzo, 1994).
Cost versus benefit analysis were affected by the prevalence rates of each individual
study, when compared to the direct and indirect cost of testing and treatment. The
prevalence rates were influenced by the sensitivity and specificity of the nonculture test,
which was most widely used for screening high risk clinic populations. In spite of these
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diflferences, studies showed that the break-even prevalence point still averaged 6% to 8%
in high risk populations.
Theoretical Framework
Betty Neuman's Systems Theory provided the conceptual framework for this study.
Her concept of secondary prevention as intervention relates to the early detection and
treatment of physiological health problems. Her concept of health is the maintenance of a
stable state. Neuman's client system model (1989) (Figure 1) represents a wholistic view
of the client. This system's core is conceptualized as being protected by three sets of
concentric rings. The core represents basic survival factors that relate to genetic response
patterns, ego structure, cognitive ability, along with the strengths and weaknesses of body
organs. The concentric rings consist of the flexible line of defense, the normal line of
defense, and the lines of resistance. A dynamic flexible line of defense represents the outer
concentric ring. The more distance between the flexible line of defense and the normal line
of defense, the greater buffer it provides for the client's normal or stable state of
health. The flexible line of defense constitutes the individual's immediate response to
stressors. The normal line of defense is the next level of protection in Neuman's client
system model. It lies between the flexible line of defense and the lines of resistance and
represents the client's ability to maintain a dynamic equilibrium. It includes those resources
for adapting to internal and external stressors that have been developed over a lifetime.
Neuman (1995) states, " . . . when the normal line of defense has been penetrated, the
client presents with symptoms of instability or illness, caused by one or more impacting
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1) Flexible Line of Defense
Le. *) Knowledge related to
prevention of STD’s
b) Use of Condoms

\ \
Basic
Stnctnre

w

\ \

2) Normal Line of Defense
Le. Famii^ Vabes
a) abstinence
b) monogamous relationslup

3) Lines o f Resistance
Le. a) Level o f physical psychological.
developmental, sociocnltiiral &
spiritual weHncss
b) Compliance with prescribed
treatment

Figure 1. Neuman's client system model.
Source: Neuman, B. (1995). Systems and nursing: Conceptualization of the Neuman
Systems Model. The Neuman Systems Model (3rd ed.) ( p.28), Norwalk, CT: Appleton &
Lange. Adapted with permission.
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stressors " (p. 27). Protecting the core is the innermost concentric ring, called the lines o f
resistance. When stressors invade the normal line of defense, the lines of resistance are
involuntarily activated in an attempt to stabilize the client's system by restoring its normal
line of defense.
Neuman’s (1995) concept of stressors includes intrapersonal, interpersonal, and
extrapersonal sources. Each source includes physiological, psychological, developmental,
sociocultural, and spiritual variables. Betty Neuman further focused on her concepts of
primary, secondary, and tertiary prevention as interventions and on reconstitution (Reed,
1993). Intrapersonal stressors relate to the client's physical functioning. For example, the
immaturity of the adolescent and young adult female's reproductive tract makes her more
susceptible to contracting a chlamydial infection (Touchstone & Davis, 1992). Also the
use of drugs and/or alcohol reduces inhibitions that consequently may increase the
incidence of multiple partners and decrease the likelihood of barrier protection being used.
Interpersonal stressors relate to the client's interaction with her external environment. For
example, having multiple partners or having a partner with multiple partners increases the
likelihood of being exposed to chlamydia. Extrapersonal stressors are also part of the
client's external environment but are more abstractly related, such as a lack of education
related to the transmission of chlamydia, and the media hype which portrays promiscuous
sexual encounters to be desirable. For example, a client's flexible line of defense may be
her knowledge related to the prevention of STD's or her use of condoms. Her normal line
of defense may be her Amily values (abstinence or a monogamous relationship) and the
environment in which she lives (a community that provides easy access to routine health
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care). Her lines of resistance may be the maintenance of a high degree of physical,
psychological, sociocultural, developmental, and spiritual wellness, and the compliance
with treatment of sexually transmitted diseases when needed (Neuman, 1995).
Neuman's Systems Theory states that once the client's normal line of defense is
broken, instability (infection) occurs. The primary concern o f health care professionals is
prevention. Therefore, Neuman's primary prevention as intervention is of prime interest.
The purpose of primary prevention as intervention is to promote client wellness by
prevention of stress and the reduction of risk factors (Neuman, 1995) (Figure 2). The first
goal is to encourage the client to protect her normal line of defense by "...a) increasing her
flexible line of defense's ability to withstand environmental stressors", for example, the use
of condoms for protection; and by "b) decreasing risk factors" (Reed, 1993, p. 14), by
remaining abstinent, maintaining a mutually monogamous relationship, or by decreasing
her number of partners. Primary prevention interventions include providing risk reduction
education and counseling and making condoms readily available.
When primary interventions are not utilized or are ineffective, secondary prevention as
intervention must be mobilized (Figure 3). Early, secondary prevention as intervention
prevents more severe illnesses fi’om occurring (CDC, 1993). In this study, secondary
prevention as intervention refers to selective screening or early testing for chlamydia and
providing early treatment when needed. Early treatment allows clients to return to a
stable state as soon as possible thus preventing the long term consequences of an
unidentified, untreated chlamydial infection (Neuman, 1995).
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1) Stxestor:
i.e. Cblamydût
2) AiSMiment of Streicor to antictpate
poiiiblfi coaaeqnancet of potential
iUneai;
i.e. Univenal Screening
for Chlamydia
/

I

4) Goal: To atrengthen flexible line-defenae:
Le. Client uaea condoma as a
prevention measure

3) Intervention to preveitt invaaion of atreaaor
Le. Reinforce need for coneietent
nae of condom#

Figure 2. Format for primary prevention as intervention model.
Source; Neuman, B. (1995). Systems and nursing: Conceptualization of the Neuman
Systems Model. The Neuman Svstems Model (3rd ed.) (p.34), Norwalk, CT: Appleton &
Lange. Copyright 1980 by Betty Neuman. Adapted with permission.
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StRHor:
Le. Chlamydia
1) Reaction to atreeaora:
Le. Preaenec of mucopurulent
diacharge

4} Qoal: To protect Boiie Structure
and facilitate WeOneaa/
Recomatniction
Le.Tieatmeat effective
in curing chlamydia

w
Basic
Structure

2) Asaeaament o f the degree of
reaction to atreaaora to facilitate
treatment/hiterventioa:
Le. Selectivea acreening for
chlamydia

3) hrtervention to reduce degree of
reaction to atreaaora:
Le. Treat forpoaitve chlamydia

Figure 3. Format for secondary prevention as intervention model.
Source: Neuman, B. (1995). Systems and nursing: Conceptualization of the Neuman
Systems Model. The Neuman Svstems Model (3rd ed.) (p.35), Norwalk, CT: ^ p le to n &
Lange. Copyright 1980 by Betty Neuman. Adapted with permission.
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The final phases of Neuman's Systems Theory are reconstitution and tertiary
prevention as intervention. Once the client is successfully treated for the chlamydial
infection, tertiary intervention is needed for reconstitution to be maintained Education and
counseling focused on compliance with prescribed treatment and prevention of future
infection were examples of tertiary prevention in this study, and reconstitution was the
return of the client's system to its pre-infectious state of well-being.

SmnmaiY.
This literature review, which included universal screening, selective screening, and
cost benefit analysis studies, pointed to the cost effectiveness of selective screening in low
prevalence populations, when nonculture test were used. Selective screening, however,
was not found to be cost efifective in high prevalence populations. According to the CDC
(1993), the Gen-Probe nonculture test has a comparable sensitivity to the DFA and EIA
nonculture test. In a 1989 article. Dr. Russell Phillips stated "In any patient population
where the prevalence of chlamydial infection is greater than 7%, routine (universal)
screening of all patients would be cost efifective" (p.93). The Centers for Disease Control
states that "... a prevalence of <5% is considered to be low prevalence" ( p. 17), and that
"High = >5%" (p. 14). Although CDC acknowledged that the 5% prevalence rate is
arbitrary, it is based on the use of nonculture tests such as Chlamydiazyme EIA, and
MicroTrak DFA, which all have approximate specificities of 99% and sensitivities of 80%.
Because universal screening was recommended for use in high risk populations, CDC's 5%
guideline was used in this study to determine whether these family planning clinics should
be designated as low or high risk populations.
34

According to the Prevention Centers of Disease Control in Atlanta (ffiUis et al., 1995),
unlike viral infections such as HTV, herpes, and genital warts; bacterial infections,
including gonorrhea and chlamydia, can be cured. It was pointed out that in Sweden, PID
has heen nearly eradicated due to collaborative ^ o rts among health care providers, policy
makers, educators, the media, as well as other related parties. If the Healthy People 2000
objective to reduce the spread of STD's in the United States is to be met, federal, state and
local authorities must allocate funds to provide widespread screening and treatment of
chlamydia. Researchers believed that the cost of treating PID and infertility, which are the
primary complications of chlamydia, far outweigh the cost of universally screening low
risk clients in high risk populations (Sellors et al., 1992).
Pgfioition o f Tsnpg

High Prevalence Population - A population with a chlamydia prevalence rate equal to
or greater than five percent ^5% ).
High Risk Group - Clients who have one or more risk factors, as assessed by the
Chlamydia Risk Assessment Tool, using the MDCH guidelines.
Low Risk Population: A population with a chlamydia prevalence rate that is less than
five percent (<5%).
Low Risk Group - Clients who do not have any risk fectors, as assessed by the
Chlamydia Risk Assessment Instrument, using the MDCH guidelines.
P- Value - The probability that the results obtained are not due to chance alone.
Prevalence Rate: - The number of identified cases of chlamydia divided by the total
sample population after the study period of seven consecutive months.
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Risk Factor - A single characteristic statistically associated with, although not
necessarily causally related to, an increased risk of contracting chlamydia.
Screening - The collection and laboratory testing of endocervical epithelial cell tissue
specimens for the presence of Chlamydia trachomatis, using a Gen-Probe collection kit.
Selective Screening - The testing of clients who have one or more risk factors for
chlamydia as defined by MDCITs selective screening protocol. The risk factors were
a) having more than one sex partner in the past 6 months, b) having a new sex partner in
the past 6 months, c) having a history of an STD in the past 6 months, d) having a
discharge or mucopurulent cervicitis, or e) having a fiiable cervbc.
Selective Screening Prevalence Rate - The number of identified cases of chlamydia,
using MDCITs selective screening protocol, divided by the total sample population at a
specific time.
Universal Screening - The testing of all clients for Chlamydia trachomatis who were
seen in one of three health department family planning clinics for an annual or initial
examinations.
Universal Screening Prevalence Rate - The number of identified chlamydia cases, using
universal screening protocol, divided by the total sample population after the study period
of seven consecutive months.
Research Questions
1. What is the prevalence rates of chlamydia in the low risk young adult females seen in
this health department’s family planning clinics?
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2. What is the prevalence rates of chlamydia in the high risk young adult females seen in
this health department’s family planning clinics?
3. Is there a significant difference in the prevalence rates between young adult females
who were considered low risk and those who were considered high risk for chlamydia?
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CHAPTERS
METHODOLOGY

Rgseargh Design
This study used a descriptive two group comparison ex postfacto/coneXaûon design
and a convenience sample to examine the risk for chlamydia. The independent variable was
the risk category as determined by the Chlamydia Risk Assessment Instrument. The
dependent variable was the outcome of the chlamydia test. Each client was given a selfreport questiormaire that assessed her risk category for the chlamydial infection. The
questionnaire was reviewed by the nurse during the client’s routine pre-exam assessment
interview. The clinician documented on the questionnaire the presence or absence of high
risk factors observed during the physical examination. An independent laboratory
determined the results of the nonculture chlamydia test.
Human Subjects
Approval for the ex-postfacto portion of this study, which involved the review,
assessment, and analysis of related client records, was also given by Grand Valley State
University's Human Research Review Committee (Appendix A). To maintain client
confidentiality, the client's clinic identification number was deleted fi'om the questiormaire
after the result were recorded and reviewed for completeness by the researcher. A
sequential record number was then assigned. When the clinic visit was completed, the risk
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assessment information was used for statistical purposes only and did not become a part of
the client's chart. All information was handled confidentially by the health department staff.
All reasonable efforts were made to maintain client confidentiality and to maintain an
unbiased, accurate collection and analysis of the data.

Instm.msat
A chlamydia risk assessment instrument (Appendbc B) was developed by the author as
a questionnaire to collect general, demographic, and risk assessment data for each client.
General information included the clinic location, client identification number, type o f visit,
and payment category. Demographic data, necessary to accurately describe the
characteristics of the sample population, included age, race, educational level, and marital
status. To assess the client's risk category, questions relating to new partners, multiple
partners, recent gonorrheal infections, presence or absence of genital discharge, and
presence or absence of a friable or mucopurulent cervix, were included. To assess other
possible risks, questions related to the presence of urinary tract symptoms, abdominal or
pelvic pain, and the use of antibiotics or vaginal products were asked.

CQDlSDl_yalidily and Reliability
The content validity and reliability of this instrument was based on the Act that the
general, demographic and risk factors questions were all previously tested. Another
contributing Actor was the limited number of people involved in specimen collection and
data analysis. The general and demographic information was the same information
collected by the health department for all client visits. Seven of the risk factors assessed,
relating to partners and clinical findings, were the same factors used by the Michigan
Department of Community Health for selective screening purposes. Additional questions
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relating to pain and the use of condoms were taken from other selective screening studies
as possible high risk factors. The question, relating to the use of antibiotics and vaginal
preparations was also taken from other studies and used to determine possible causes of
negative results. This questionnaire and those used in other studies were limited by the
information shared with us by the clients and by the estimation that 50% to 80% of clients
with chlamydia are asymptomatic.
Several colleagues with experience developing questionnaires reviewed the instrument.
It was pilot tested during two family planning clinic sessions at one clinic site.
Modifications made were to have clients specify age, rather than select from an age group
and to specify a co-pay category, rather than select from a co-pay range group.
There was only one nurse practitioner and one physician collecting specimens in this
study, and the nurse practitioner was the only researcher involved in the study. Both the
nurse practitioner and the physician were trained in the proper technique for specimen
collection, according to the Gen-Probe manufecturer instructions. The results were
determined by an independent laboratory.
Study Site and Subjects
In 1996, the health department conducted a study that assessed the risk factors of their
family planning clinic populations, to reevaluate their current selective screening protocol
for chlamydia. Two of their urban clinics (having the highest prevalence rates from 19921994) and one rural clinic (prevalence rate unknown) were chosen for this study. Four

hundred and three female subjects were screened for chlamydia. All were clients between
20 to 39 years of age who were seen for an initial or aimual examination, during the seven

consecutive months of this study. The Michigan Department of Community Health
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supported this study by making the chlamydia nonculture specimen collection kits (GenProbe) available to the health department at a reduced cost and assumed the cost of the
laboratory testing.
Procedure
When the client came into the clinic for her scheduled initial or annual family planning
examination, she was given a self-report questionnaire to complete along with other clinic
forms. A clinic nurse reviewed the questionnaire with each client during her routine
pre-exam assessment interview. Explanations and/or clarifications were provided by the
nurse as needed. Each client was then seen by a nurse practitioner or physician, and a
endocervical specimen was taken during a routine pelvic examination. A Gen-Probe
specimen collection kit, containing two Dacron swabs with diluent, was used to collect
each specimen. The chlamydia specimen was taken before other specimens such as the Pap
smear or gonorrhea culture. Excess cervical mucous was removed with the first swab and
discarded. The second swab was used to collect the chlamydia specimen. To insure the
collection of sufficient endocervical cells necessary for an accurate test, the Dacron swab
was placed into the cervical os and rotated for 30 seconds. Gen-Probe has a sensitivity of
90% and a specificity of 100% (Miettinen, Vuorinen, Varis, & Hallstrom, 1995). After
placing the second swab into the collection bottle with the diluent, the top of the swab was
broken off near the top of the container and the cap screwed on tightly. The specimen was
labeled with the client’s name, identification number, and date. After completing each
examination, the clinician recorded the presence or absence of a fiiable or mucopurulent
cervix on the bottom of each survey. The specimen was mailed to the processing
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laboratory at the end of that clinic day. V^thin five to seven working days the laboratory
mailed the results back to the clinic and the results were recorded on the questionnaire.
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CHAPTER 4
DATA ANALYSIS

This study compared the chlamydia prevalence rates of the low and high risk groups,
within a health department's Amily planning clinic, using the Gen-Probe nonculture test.
The purpose of this study was to detennine a) the prevalence rates of chlamydia in
designated low risk groups, b) the prevalence rates of chlamydia in designated high risk
groups, and c) if there was a significant difference between the prevalence rates of these
two groups.
Sample Characteristics
The sample consisted o f403 adult females, aged 20 to 39, seen in one of three family
planning clinics within a local health department. During a period of seven consecutive
months, all nonpregnant clients who were seen in these clinics for annual exam (60.8%) or
an initial examination (39.2%), were included in this study (Table 6). All of the clinics
were located outside a metropolis. Sites A and C were urban clinics having 47 and 297
participants respectively, and Site B was a rural clinic with 59 participants. Family incomes
were as follows a) 80.9% had incomes of <100% of the poverty level, which qualified
them for no cost family planning services, as identified by a 0% co-pay; b) 18.1% had
incomes of 100% to < 175% of poverty and were billed 20% to 60% of the total visit
cost, and c) 1% had incomes >175% of poverty and were billed 80% to 100% of the clinic
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Table 6.
Type Visits and Percentage of Co-Pav for Each Clinic
Site A
11.7%
(n = 47)

SiteB
14.6%
(n = 59)

SheC
73.7%
(n = 297)

All Sites
100%
(N = 403)

Initial

38.0%

57.6%

35.7%

39.2%

Annual

61.0%

42.4%

64.3%

60.8%

0%

91.5%

76.3%

80.1%

80.9%

20%- 60%

8.5%

. 22.1%

18.8%

18.1%

80%-100%

0%

1.7%

1.0%

1.0%

Type Visits

% of Co-Pay

cost. All fees and co-pays were assessed on the date of their clinic visit using the 1996
WCHD/ Federal guidelines (Department of Health & Human Services, 1996). Forty-five
percent of the total sample were between the ages of 20 and 24 years of age and 54.8%
were 25 years and older (Table 7). The mean age was 25.97, with a standard deviation of
4.7. The racial makeup consisted of 65.5% White, 31.0% Black, and 3.5% other. Of all
the subjects in this study, 13.3% of them had not completed high school, 36.1% were high
school graduates, 43.9% had completed some college credits, and 6.8 % were college
graduates. The largest percentage of the sample were single, not living with their partner
(49.9%). The rest of the sample were more evenly distributed with 19.2% single, living
with partner, 16.2% married; and 14.6% were separated, divorced or widowed.
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Table 7.
Comparison of Demographic Data Prevalence Across Sites
Site A

SiteB

SiteC

All Sites

11.7%

14.6%

73.7%

100%

20 - 24 years

45.2%

44.1%

46.5%

45.2%

> 25 years

54.8%

55.9%

53.5%

54.8%

Black

91.5%

13.6%

24.9%

31.0%

White

8.5%

83.0%

71.0%

65.5%

Other

0%

3.4%

4.1%

3.5%

<I 1th grade

0%

22.0%

13.6%

13.3%

High school grad

25.5%

40.4%

36.9%

36.1%

Some college

66.0%

33.3%

42.4%

43.9%

College graduate

8.5%

3.5%

7.1%

6.8%

Single not living
with partner

68.1%

42.4%

48.5%

49.9%

Single living
with partner

14.9%

16.9%

20.3%

19.2%

Married

6.4%

25.4%

15.9%

16.2%

Sep/Div/Wid

10.6%

15.3%

15.2%

14.6%

Clients
Age

Race

Education

Marital status

Demographically Sites B and C were quite similar. Seventy-one percent to 83% were
White, 42.4% to 48.5% of the clients were single and not living with their partner, and
33.3% to 42.4% had some college education. Also noted was that 76.3% to 80.1% had a
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0% co-pay. Site A identified a much higher percentage of Black participants (91.5%), a
slightly higher percentage of 0% co-pays (91.5%), with 68.1% of the clients identified as
single and not living with their partners. In addition. Site A had a higher percentage of
subjects with some college (66.0%) and a slightly higher percentage of college graduates
(8.5%) than Site C. Site C was shown to have 7.1% college graduates, according to the
self-report questionnaire, and Site B reported the lowest percentage (3.5%) of college
graduates.
Risk Factor Results
Although having sex without using a condom is not one of MDCITs criteria for
selective screening, failure to use condoms was assessed as a possible risk factor for
chlamydia. Of the 403 subjects screened, the mean prevalence for those who had sex
without using condoms, sometime in the last six months, was 72.3% (290).
Seven risk factors were used to differentiate the high risk groups fi*om the low risk
groups (v^pendix C). The most frequent MDCH selective screening risk factor, identified
in this health department, was having a new parmer (20.6%) in the past six months. The
prevalence of risk factors among those clients who tested positive for chlamydia were as
follows a) having a new partner in the past sbc months (45.5%) (Appendix D); b) having
more than one partner in the past six months (25.0%); c) having a friable cervix on
examination (16.7%); d) the client or her partner having an unusual discharge (16.7%);
e) having a partner who has had more than one partner in the past six months (9.1%);
f) having a mucopurulent cervical discharge on examination (8.3%); and g) the client or
her partner having had gonorrhea in the past six months (8.3%). If none of the previous
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risk factors were identified, the client was designated as low risk. If any of the previous
risk factors were identified the client was designated as high risk. If there were no
response checked (yes or no) on any one of the risk Actor questions, and no other high
risk factor was indicated, the case was counted as missing.

Chlamydia Prevalgnçg Ratgs
The prevalence rates for chlamydia in the low risk groups were Site A, 6.4%, Site B,
0%, Site C, 0.3%, and the mean low risk prevalence rate was 1.0% (Table 8). The mean
high risk group prevalence rate was 1.8%. Site A's high risk group prevalence rate was
6.4%; Site B 1.8%, and Site C was 1.0%. The total chlamydia prevalence rates of each
clinic (Table 9), which included both the low risk and the high risk groups, were Site A,
12.8%, Site B, 1.7%, Site C, 1.7%, and the mean rate was 3.0%.
A chi-square test with Yates correction was used to compare the test outcome with
the risk designator. There was no significant difference in the diagnosis of a chlamydial
infection, between the clients who were designated as low or as high risk, in any of the
clinics or in the combined population. (Chi Square =1.8, df = 1, p = . 18). The total clinic
prevalence rates in Site B of 1.7% and Site C of 1.7% were well below the 5% prevalence
rate that CDC uses as a guideline to determine the low risk from the high risk groups.
Site A however, whose prevalence rate was 12.8%, was well above 5%. Also their low
risk group's prevalence rate (6.4%) was equal to that of their high risk group's prevalence
rate (6.4%). According to Dr. Phillips (1989), as well as multiple other universal and
selective screening studies. Sites B and C fit into the selective screening category based on
their low prevalence rates, even though there was no significant difference between their
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Table 8.

Chlamydia;. UiûYsrsal Sçrggnins Results
Low Risk
Positive

High Risk
Positive

Low Risk
Negative

High Risk
Negative

Totals

Site A

6.4%
(3)

6.4%
(3)

46.8%
(22)

40.4%
(19)

100%
(47)

SiteB

0%
(0)

1.8%
(1)

56.1%
(32)

42.1%
(24)

100%
(57)

Site C

0.3%
(1)

1.0%
(3)

62.0%
(183)

36.7%
(108)

100%
(297)

Combined
Sites

1.0%
(4)

1.8%
(7)

59.4%
(237)

37.8%
(151)

100%
(399)

Note. Nfissinecases: SiteB (2 )negatives
Site C (1) negative & (1) positive

Table 9.
Universal Screening Prevalence Rates
Total Participants

Total Positives

Site A

47

6

12.8%

SiteB

59

1

1.7%

SiteC

297

5

1.7%

Combined Sites

403

12

3.0%

Prevalence Rates

low risk and high risk groups. Site A, however, fits into the universal screening category
based on their prevalence rate o f 12.8% being well above 5%, and because there was no
significant difference between their low risk and their high risk groups.
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OthsT-findings
Additional questions were added to assess other possible high risk factors for those
testing positive for chlamydia. Included were clients who had a) sexual intercourse at
anytime in the past six months without using condoms (91.7%); b) used antibiotics,
vaginal medications, or douched in the past 48 hours (18.2%); c) lower abdominal or
pelvic pain at the time of examination (8.3%); or d) pain, burning, or frequency of
urination (0%).
In order to determine if a lack of knowledge relating to their partners history had an
influence on the subjects ability to accurately respond to some of the questions on the risk
assessment form, a "dont know" category was added to two of the questions. The first
question asked was had their "partner had more than one partner in the last six months?"
A third (36.4%) of the participants answered "dont know". The second question asked
was had their "partner had a positive test for gonorrhea in the past six months?" A
smaller percentage (16.7%) of those responding indicated that they didnt know.
There were no significant differences in the other chlamydia prevalence rates or in the
risk factors used to predict the risk for the low and high risk groups. One point of focus
was that 72% of the total client sample population reported having had sexual intercourse
without using condoms at least once within the last sbc months, but only 35.4% reported
being married or living with their partner. Eleven (91.6%) of those testing positive
admitted to having sex without a condom at sometime during the past sbc months, but one
subject denied doing so. This supports the belief that chlamydia can persist for up to 15
months as stated in the Primary Care Update (1994).
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When looking at other factors, all clients with a positive test were in the 0% co-pay
category, indicating that they reported an income below poverty level. Seventy-five
percent were single, and none were college graduates. Although there was a total of 403
participants in this study, the total number of subjects with a positive test for chlamydia
(12) was too low to adequately test the risk assessment screening criteria.
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CHAPTERS
DISCUSSION

Smrniary and CgoslysioQ
Adult females (N=403) from three clinical sites were universally screened for
chlamydia risk factors, using a self-report chlamydia risk assessment form. Clients were
accustomed to filling out the HIV risk assessment questionnaire, as part of the health
departments routine interviewing process. This may have contributed to their
cooperativeness in completing this chlamydia risk assessment instrument. The risk
assessment tool also provided the nurses with a more structured format in which to
discuss this, often silent, STD.
Based on the client's responses on the questionnaire, she was placed in either a low
risk or a high risk group and tested to determine if a chlamydial infection was present.
Twelve (3.0%) subjects tested positive. The primary purpose of this study was to
determine if the use of the risk assessment tool to classify clients as low or high risk would
accurately predict the results of a test for Chlamydia trachomatis. The secondary purpose
was to determine the chlamydia prevalence rate at each clinic. Each clinic was then
categorized as a low or high risk population, using CDC's S% guideline. After analyzing
the results, 241 (60.4%) were classified as low risk while 158 (39.6%) were placed in the
high risk category with four missing cases. Four (1.0%) of the 12 subjects with chlamydia
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were in the low risk group and seven (1.8%) were in the high risk group with one missing
case.
The conclusion was that the mean prevalence rate of the health department's family
clinics was 3% which categorized it as a low risk population. Sites B and C both had
prevalence rates of 1.8% each, which is consistent with the mean rate categorization.
Site A, however, had a prevalence rate of 12.8%. Having a rate > 5% places Site A in the
high risk category, and should, therefore, be evaluated independent of Sites B and C.
Having less than a ninth grade education was reported by Holmes et al. (1993), to be a
risk factor for chlamydia; however, Addiss et al. (1987) stated there is no relationship
between a positive chlamydial infection and education. In addition, none of the other
studies, documented in this literature review, assessed this relationship. In this study.
Site A with a prevalence of 12.8%, reported the highest rate of clients with college
degrees or with some college education (74.5%). This was compared to 49.5% at Site C
and 36.8% at Site B, even with almost identical mean ages.
Also of interest are the findings related to race. In the literature review Handsfield
et al. (1986), Addiss et al. (1987), and Han et al. (1993) reported no relationship existed
between race and a chlamydial infection. Only CDC (1994) reported the presence of a
relationship. Although five of the sbc clients with a positive test in Site A were Black, the
prevalence was only 11.6%, while the prevalence for Whites was 25%. The greater
number (5 out of 6) was most likely related to the fact that 91.5% of the clients at Site A
were Black.
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Another point of interest was the relationship between low income and the presence of
chlamydia. Although it was not discussed in the literature reviews, it was noted that all the
clients with a positive chlamydia test in this study, and 91.5% of Site A's total sample
group reported incomes below the poverty level. Again, because there were only 12 cases
of chlamydia identified in this study, no determination of differences in physical or
socioeconomic risk factors could be made between those with or without chlamydia or
among the three sites.
Taking a closer look at the clients at Site A who had chlamydia, compared to those
who did not have chlamydia, the following data was noted for demographic variable
categories (Table 10). Of those with chlamydia, 66.7% were age 24 or younger, while
only 34% of those without chlamydia were in this age bracket. Thirty-three percent of
clients with chlamydia were single and living with a partner. None were married or
divorced. Of those without chlamydia, 12% were single and living with a partner, while a
similar percentage were divorced, separated or widowed, and 7% were married. White
clients comprised 16.7% of those with chlamydia and 7.3% of those without chlamydia.
There was approximately the same percentage of clients with chlamydia as those without
who were Black, high school graduates, or with some college education, and those who
were single and not living with their partner. The most prominent social risk factor was
having sex without using a condom (83.3% vs 53.7%), as compared to those who did not
have chlamydia (Table 11). Other risk factors were a) having multiple partners (33.3% vs
17.1%), b) having a partner with multiple partners (16.7% vs 9.8%), c) having a new
sexual partner (33.3% vs 22%), and d) having an unusual discharge (33.3% vs 22%).
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Table 10.
Site A Client Demographics: With and Without Chlamvdia
With Chlamydia
n=6

Without Chlanqrdia
n = 4I

Total Site A
n = 47

20 - 24 years

66.7% (4)

34.1% (14)

38.3% (18)

>25 years

33.3% (2)

65.9% (27)

61.7(29)

Black

83.3% (5)

92.7% (38)

91.5% (43)

White

16.7% (I)

7.3% (3)

8.5% (4)

High school graduate

33.3% (2)

24.4% (10)

25.5% (12)

Some college

66.7% (4)

65.9% (27)

66.0% (31)

College graduate

(0)

9.8% (4)

8.5% (4)

Single not living
with partner

66.7% (4)

68.3% (28)

68.1% (32)

Single living
with partner

33.3% (2)

12.2% (5)

14.9% (7)

Married

(0)

7.3% (3)

6.4% (3)

Sep/Div/Wid

(0)

12.2% (5)

10.6% (5)

AGE

RACE

EDUCATION

MARITAL STATUS

Limitations and Recommendations
The fact that only 12 subjects tested positive was a major limitation of this study. The
number of subjects with chlamydia was too low to statistically test the risk assessment
tool's ability to accurately predict test results. However, the fact that Site A had a 12.8%
prevalence rate indicated that it should be considered a high risk population at this time.
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Table 11.

Sits A Client RiskJEagtprs: With and.Withoyt Chlamydia
With Chlamydia
n=6

Without Chlamydia
n = 41

Total Site A
N = 47

New partner < 6 months

33.3% (2)

22.6% (9)

23.4% (11)

Multiple partners ( n ç )
< 6 months

33.3% (2)

17.1% (7)

19.1% (9)

Yes

16.7% (1)

9.8% (4)

10.6% (5)

D o n 't know

33.3% (2)

22% (9)

23.4% (11)

Gonorrhea - self or partner
tx < 6 months
Yes

16.7% (1)

2.4% (1)

4.2% (2)

D o n 't know

16.7% (1)

12.2% (5)

12.8% (6)

33.3% (2)

22% (9)

23.4% (11)

No

16.7% (1)

46.3% (19)

42.6% (20)

Yes

83.3% (5)

53.7% (22)

57.4% (27)

(0)

7.3% (3)

6.4% (3)

Abdominal^elvic pain

16.7% (1)

24.4% (10)

23.4% (11)

Antibiotics, vaginal meds, or
douching <48 hours

16.7% (1)

14.6% (6)

14.9% (7)

Mucopurulent cervicitis (MPC)

16.7% (1)

14.6% (6)

14.9% (7)

(0)

14.6% (6)

12.8% (6)

Partner with n^)

Unusual discharge
Sex without condoms

Pain, burning or hequency of
urination

Friable cervix

Both the prevalence rates of the high risk group in Site A (6.4%, 3) and the low risk group
(6.4%, 3) were equal. This indicates that further study is needed to detennine if the
assessment tool, based on the MDCH screening criteria, is adequate to determine who
should or should not be screened. It was, therefore, recommended that universal screening
be continued at Site A until that determination can be made. Although there was no

55

significant difiference between the low risk and the high risk groups at Sites B or C in
relation to the number of positive results obtained, their mean prevalence rates fell well
below the 5% prevalence rate. Therefore, universal screening was terminated and selective
screening protocols were resumed.
Because Site A is a high risk population (12.8%), as opposed to the low risk
populations of Sites B and C (1.8% each), future study using the Health Belief Model was
recommended to assess the beliefs, values, and attitudes of that population toward
sexually transmitted diseases and the use o f primary prevention measures. The Health
Belief Model (HBM) assumes that the client must a) believe that her health is in jeopardy,
b) perceive the potential seriousness of having complications related to an untreated
chlamydial infection, c) believe that the benefits firom the recommended behavior outweigh
the costs or inconvenience and are within her ability to do, and d) have a "cue to action"
that makes her feel the need to use primary preventive measures (Green & Kreuter, 1991).
According to Simon and Das (1984), it is helpful to assess data on a group's
perception of various aspects of the HBM prior to developing an educational program for
a particular group, such as Site A These authors recommended the use o f the Venereal
Disease (VD) Education Health Belief Model Scale Dimensions in analyzing similar
populations. This model uses a 5-point scale ranging Grom strongly agree to strongly
disagree to rate several questions in five major scale categories. These scales are the
Susceptibility Scale, Seriousness Scale, Barrier Scale, Benefit Scale, and the Likelihood
Scale (Appendk E). Examples of questions on these scales are a) Susceptibility Scale;
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I am too young to have venereal disease, b) Seriousness Scale: an attack of gonorrhea
might make me unable to have children, c) Barrier Scale: I am too embarrassed to go for
VD checkups, and d) Benefit and Likelihood Scale: telling my sexual partner(s) if I
suspect that I have VD. Once this data has been collected and assessed, health
professionals can tailor a program more suited to the specific needs of Site A's high risk
population. Although this model by Simon and Das is an excellent model, it is
recommended that it be updated to reflect the change in terminology fi'om the use of
Venereal Disease (VD) to the current use of Sexually Transmitted Disease (STD). Also
recommended is a change reflecting the current recommendation for yearly physical
examinations, unless otherwise indicated.
Other limitations of this study included the use of convenience sampling, whereby
clients were self-selected by coming to one of the three pre-selected clinics, pre-designed
for use by low and no income clients. Due to the limited number of available participants,
random sampling was not recommended.
Prior studies have shown that although there are many risk factors that may place a
client in the high risk category for chlamydia, the only consistent demographic risk factor
found is being less the 20 years of age (Wiesmeier et al., 1984; Handsfield et al., 1986;
Addiss et al., 1987; Han et al., 1993, & CDC, 1994). Because there has been no single
physical risk factor or group of risk factors identified as a positive predictor for this
sexually transmitted disease, further studies are needed. One of the most frequent
recommendations is for further development of less costly, less invasive, and more
sensitive test that would make widespread universal screening practical. At the present
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time the development of a more sensitive rapid stat test would be beneficial. Due to the
dffîculty encountered with cbent follow-up such as a) contacting clients in a confidential
manner, especially with the new caller id, b) inaccurate phone numbers and/or addresses
given by the clients, c) the transient nature of cUents, as well as d) clients who do not
return for treatment when notified, having a rapid stat test, whereby results can be
available (in < 30 minutes) while the client is still in the clinic, would be a major
advantage. This would facilitate providers in prescribing immediate treatment based on a
more definitive diagnosis as opposed to treatment based on a presumptive diagnosis, or
delaying treatment while chlamydia results are pending. The current rapid stat test,
however, detects all three chlamydia species, has a high false-positive rate, and has a
sensitivity of only 48.5% (Hook HI, Spitters, Reichart, Neumann & Quinn, 1994).
Although several high risk factors have been identified, no one factor or group of
factors has been found to be a reliable positive predictor for chlamydia. Unfortunately,
most of the risk factors are based on client self-report of their own behavior as well as
their knowledge of and willingness to report their partner's behavior over the past six
months. For example, clients are asked a)"Have you had a new sexual partner?" b)"Have
you had more than one partner?" c)"Has your partner had more than one partner?" and
d)"Have you or your partner had a positive test for gonorrhea or an unusual discharge?"
Sharing such confidential information with virtual strangers is fi'equently difihcult for some
and unthinkable for others. If there was some way to elicit more reliable responses fi'om
clients, it would most likely increase the positive predictive values of the current risk
factor criteria. Establishing a more trusting climate, whereby the client is able to share
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sensitive information more openly, whether it is written or verbal, is the crucial first step.
Some clients may be willing to share the requested information but may not be reliable
because t h ^ have not discussed these issues with their partner(s), or their partners have
not been truthful with them. Encouraging clients to establish better communication
between them and their partners, so that they are more knowledgeable about their
partners, is another necessary step. The third step is to reduce the cost of testing so that it
is available to all sexually active clients as part of their routine gynecological examination.
Doing so would minimize the risk of developing complications of an untreated chlamydial
infection. The fourth step is to follow up on client contacts, as recommended by the CDC
(1993), so that asymptomatic partners do not go untreated and unknowingly spread the
infection to others.
Theoretical and Clinical Implications for Nursing
Extensive selective screening studies have been done, and several high risk factors
have been identified for the chlamydial infection. Betty Neuman's concept of primary
prevention as intervention can, therefore, be used as a basis for educating the public in
general and the client in particular about risk reduction methods. Primary prevention
focuses on the protection of the flexible line of defense fi'om invasion by a stressor such as

Chlamydia trachomatis. The challenge to health professionals is to a) provide education
as needed, b) activate client acceptance and/or motivation, and c) assist clients in
developing or mobilizing skills needed to negotiate parmer cooperation in utilizing primary
prevention measures. For example, maintaining a mutually monogamous relationship
and/or the consistent use of condoms are the primary means of risk reduction for
59

chlamydia and other STD's. Therefore, the more effective health professionals are in
assisting clients to utilize these primary preventive measures, the greater impact they will
have in reducing the prevalence rate of chlamydia. In line with Neuman's primary
prevention model, many states have mandated low income family planning and STD clinic
services for local communities. Providing fiedble hours and user Mendly clinic services
will enhance the clients desire and willingness to use them when needed. Neuman's
secondary prevention as intervention focuses on early detection of diseases, such as
chlamydia, and provides for treatment prior to or at the early onset of symptoms.
Universal and selective screening can be utilized to detect sexually transmitted diseases
prior to the onset of symptoms. Selective screening can be used to detect chlamydia and
provide treatment when symptoms first occur. Because chlamydia has been labeled the
silent STD, selective screening for contact follow-ups is the best means for early treatment
of asymptomatic partners. Neuman's Systems Model can be effectively used by health care
professionals in developing services for the prevention, early detection and treatment of
chlamydia and other sexually transmitted diseases.

Chlamydial trachomatis is a bacterial infection that can be easily treated with one oral
dose of Azithromycin or by taking Doxycycline twice a day for seven days. Therefore, it is
up to all health care providers to offer screening and treatment to their sexually active
clients. Universal screening is recommended if their site prevalence rate is >5%, and
selective screening if their prevalence rate is < 5%. Failure to do so places clients at undo
risk, and the money saved by failing to screen clients will be lost in treating clients who
experience complications such as FID or infertility.
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As a result of this study, the NCchigan Department of Community Health approved
universal screening at Site A, which is currently in effect. This decision was based on
Site A's high prevalence rate of 12.8%, as compared to the 1994 local out county and
state prevalence rates of 7.9% and 5.08% respectively. Selective screening was
subsequently resumed at the low prevalence Sites B & C.
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APPENDIX A
Human Research Review

kGRAND
IVStUUEY
_ 'STATE
UNIVERSITY
1CAMPUS OM Ve •

ALLENOALE •

September 9, 1996
Verneal Y. Glispie
19591 Nadol Drive
Southfield. M I 48075
Dear Verneal;
The Human Research Review Committee o f Grand Valley State University is charged
to examine proposals with respect to protection o f human subjects. The Committee
has considered your proposal. "Chiamydia Screening: Universal vs. Selective
Screening P ro to co r, and is satisfied that you have complied with the intent o f the
regulations published in the Federal Register 46 (16): 8386-8392. January 26, 1981.
Sincerely.
cA -

eO

Howard Stein. Acting Chair
Human Research Review Committee
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APPENDIX B

Wayne County Department of Health

(Pagei of 2)

Location:

Client ID#_________________

_

I) Highland Park
2) Sumpter
3) Westland

_

Date_____________________

Chlamydia Risk Assessment
This infonnatioa is completely voluntary and strictly confidential. It will not be
part of your medical record here. This information will be helpful for statistical and
planning purposes. Do not write your name on this sheet.
1) City of residence;______________________ Zip Code_____________________.
2) Type of visit: (I) Initial
3) Age:

,

, (2) Annual________ , (3) Other

Birthdate:______________________________

4) Race/Ethnicity (I) Black
(4) Asian/Pacific Islander

, (2) White
,

, (3) American Indian

(S)Alaskan Native

, (6)) Hispanic

, (8) Other___________________________ .

(7) Arabic

5) Highest grade completed: (I) Less than 8th

, (2) 8th-llth______

(3) High School Grad_______, (4) Some College______ , (5) College Grad
6) What percentage of your family planning bill are you expected to pay? Ask clerk
(1) 0%

(2) 20% ___ , (3) 40%

(4) 60% ___, (5) 80%

, (6) 100%___.

7) Marital Status:
(1) Single (not living with partner)
(3) Married

, (4) Separated

, (2) Single (living with partner)_______ ,

, (5) Divorced_______ ,(6)Widowed____ .
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Appendix B (continued)

(Page 2 of 2)

8) Have you had a new sexual partner in the last six months?— (0) No

(1) Yes__

9) Have you had more than one sex partner in the last six months? (0) No_, (l)Yes_
10) Has a partner of yours had more than one partner in the last six months?-------------------------------------------- (0) No

, (1) Yes

, (2) Dont know______

11) Have you or a partner had a positive test for gonorrhea in the last six months?--------------------------------------- (0) N o

, (1) Yes

, (2) Don’t know______

12) Do you or a partner have an unusual discharge?----------- (0) No

(1) Yes____

13) In the last six months, have you ever had sexual intercourse without using a
condom?------------------------------------------------------------(0) No____(1) Yes___
14) Do you have frequent, burning, or painful urination ? — (0) N o

(1) Yes___

15) Do you have lower abdominal or pelvic pain ? ------------- (0) No

(1) Yes_____

16) Have you used any type of antibiotics, vaginal creams, jellies, suppositories or
douches in the past 48 hours?

(0) No

(1) Yes____

If you have any additional questions or concerns, you may discuss them
with the staff during your visit today. Please return this sheet to one of the health
care providers today. Thank you for helping us to help you.
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!STOP HERE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Interviewing Nurse______________________________
**T0 BE RECORDED BY Physician/Nurse Practitioner;
**17) Mucopurulent discharge present?
____________ (0) No
(1) Yes____
**18) Friable cervix ? ------------------------------------------------- (0)N o___ (1) Yes____
19) R ESU LTS of chlamydia test-------------------- ( 0) Negative___ (I) Positive___
20) Risk le v e l --------------------------------------------------- ( 1) Low___ (2) IBgh
VYGAKAT/D4/9
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APPENDIX C
Comparison of Chlamydia Risk Factor Prevalence Across Sites
Site A n = 47
Sex V^thout Condoms

SiteB n = 59

S heC n = 297

All Sites N =403

Yes

(27) 57.4%

(47) 79.7%

(216) 73.2%

(290) 72.3%

No

(20) 42.6%

(12) 20.3%

(79) 26.8%

(111) 27.7%

Yes

(11) 23.4%

(9) 15.3%

(63) 21.3%

(83) 20.6%

No

(36) 76.6%

(50) 84.7%

(233) 78.7%

(319) 79.4%

(9) 19.1%

(4) 6.8%

(36) 12.1%

(38) 80.9%

(55) 93.2%

(261) 87.9%

Missing Cases (2)
New partner

Missing Cases (I)
Multiple Partners (n ^ )

(49)

12.2%

Yes
No
Missing Cases

(354) 87.8%

(0)
Yes

(5) 10.6%

No

(31) 66.0%

(47) 85.5%

(222) 75.5%

(300) 75.8%

D ont Know

(11) 23.4%

(7) 12.7%

(51) 17.3%

(69) 17.4%

Yes

(11) 23.4%

(6) 10.3%

(25) 8.4%

(42) 10.5

No

(36) 76.6%

(52) 89.7%

(271) 91.6%

(359) 89.5%

Yes

(11) 23.4%

(8) 13.6%

(48) 16.2%

(67) 16.6%

No

(36) 76.6%

(51) 86.4%

(249) 83.8%

(336) 83.4%

Yes

(7) 14.9%

(4) 6.9%

(31) 10.5%

(42) 10.5%

No

(40) 85.1%

(54) 93.1%

(264) 89.5%

(358) 89.5%

Yes

(7) 14.9%

(5) 8.5%

(11) 3.7%

No

(40) 85.1%

(54) 91.5%

(286) 96.3%

Partner with mp

Missing Cases
Unusual discharge

Missing Cases
Abdominal / Pelvic pain

Missing Cases

(1)

1.8%

(21)

7.1%

(27)

6.8%

(7)

(2)

(0)

Antibiotics, vaginal meds,
or douching <48 hours

Missing Cases
Mucopurulent cervicitis
Missing Cases

(4)

(3)
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(23)

5.7%

(380) 94.3%

APPENDIX D
Risk Factors for Clients With Chlamydia

Site A
n=6

SiteB
n= 1

SiteC
n= 5

ALL SITES
N= 12

New partner < 6 months

(2) 33.3%

(1) 100%

(2) 50%
1 missing case

(5) 45.5%

Multiple partners (mp )
< 6 months

(2) 33.3%

(0)

(1) 20%

(3) 25.0%

Yes

(1) 17%

(0)

(1) 20%

(1)

Don"t know

(2) 33.3%

(0)

(1) 25%
1 missing case

(4) 36.4%

(1) 17%

(0)

(0)

(1) 8.3%

(1) 17%

(0)

(1) 20%

(2) 16.7%

(2) 33.3%

(0)

(0)

(2) 16.7%

No

(1) 16.7%

(0) 0%

(0) 0%

(1) 8.3%

Yes

(5) 83.5%

(1) 100%

(5) 100%

(11)91.7%

Pain, burning or
frequency of urination

(0)

(0)

(0)

(12) 100%

Abdominal/pelvic pain

(1) 17%

(0)

(0)

(1) 8.3%

Antibiotics, vaginal meds,
or douching <48 hours

(1) 17%

(0)

(1) 25%
1 missing case

(2) 18.2%

(1) 17%

(0)

(0)

(1) 8.3%

(0)

(1) 100%

(1)20%

(2) 16.7%

Partner with mp

Gonorrhea - self or
partner tx < 6 months
Yes
Don"t know
Unusual discharge

9.1%

Sex without condoms

Mucopurulent cervicitis
(MPC)
Friable cervix
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APPENDIX E
Items Comprising the VD Education HBM Scale Dimensions
(Each item rated along a 5-point scale from Strongly Agree to Strongly Disagree)
1) Strongly Agree
2) Agree
3) Unsure
4) Disagree
5) Strongly Disagree
Susceptibility Scale
1 .1 cannot contract VD because I/my sexual partner(s) douche after sexual intercourse.
2 . 1 am too young to have venereal disease.
3 .1 am very healthy so my body can fight off venereal disease.
4 . 1 take a bath every day with soap and water, so I am not likely to catch venereal
disease.
5 .1 cant catch venereal disease because I always use a clean toilet seat.
6. My religious teaching has been very good, so I cannot contract venereal disease.
7. My sexual partner(s) has/have resistance to venereal disease, so I cannot get VD.
8 .1 caimot contract VD because my sexual partner(s) use the pill (oral contraceptive).
9. People like me dont get VD.
10.1 cannot contract VD because my sexual partner(s) is/are always very clean.
11. If I had a venereal disease and got treated, I could not contract it again.
12. If I had syphilis, I could not have gonorrhea at the same time.
Seriousness Scale
1 .1 think gonorrhea is a serious disease because it may damage my heart in the long run.
2. An attack of gonorrhea might make me unable to have children.
3. Venereal disease is more serious than most other diseases.
4. In my opinion gonorrhea is a serious disease because it may eventually cause arthritis.
5 .1 dont believe that VD is a serious disease because it is not going to kill me.
6. Contracting VD will disturb my peace of mind.
7. If I contracted VD, it would seriously disturb my family relations.
Banier Scalg
1 .1 dont go for VD checkups because I am afi-aid other people in the clinic might think I
have VD.
2 .1 am afraid of pain during VD checkups.
3 .1 don't want to go for VD checkups because the examination might show that I have
VD.
4 . 1 don't go for VD checkups because I have no time to do so.
5 .1 am embarrassed to go for VD checkups.
6 .1 dont like to go for VD checkups because Fm afraid the doctor might not be
considerate o f me.
7 .1 don't go for VD checkups because I dont know the location of VD clinics.
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Appendix E (continued)
Items Comprising the VD Education HBM Scale Dimensions
8 .1 am hesitant to go to VD clinics because the clinic workers may tell others about my
visit.
9 .1 am unable to afford the cost of periodic VD checkups.
10. VD clinic hours are inconvenient for me.
11. If I were infected with VD, I would be reluctant to disclose the name of all my sexual
partners to protect my privacy.
12. If I were infected with VD, I would be reluctant to disclose the name of all my sexual
partners to protect their privacy.
Benefit Scale and Likelihood Scale
*These two scales comprise the same 14 items considered fi-om a different perspective.
* For the Benefit Scale, the items were answered in response to "How strongly do you
agree that the following actions are useful in controlling and preventing venereal
disease?"
* For the Likelihood Scale the items were answered in response to "How likely are you
are you to take the following actions in order to prevent the control of venereal
disease?"
1. Refusing sexual activities with casual sexual partners who would not accept the use of
a condom (rubber).
2. Avoiding sexual intercourse with persons who have many sexual partners.
3. Refusing sexual relations with anyone who I know has had VD.
4. Examining my genital area regularly for signs of VD infection.
5. Examining regularly the genital area of my sexual partner(s) for any sign of VD
infection.
6. Carrying a condom (rubber) at all times for use whenever I have sexual intercourse
with a casual sexual partner.
7. Seeking immediate medical advice if I suspect that I have contracted a venereal
disease.
8. Telling my sexual partner(s) if I suspect that I have VD.
9. Washing the genital area with soap and water immediately after sexual intercourse.
10. Releasing the names of all my sexual contacts to the VD clinic authorities if I am
diagnosed as having VD.
11. If infected with VD, avoiding sexual activities (even after treatment) until the cure is
verified by a physician.
12. Encouraging anyone I suspect of having VD to seek immediate medical help.
13. Getting regular V D checkups a minimum of four times a year for early diagnosis of the
disease.
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Appendix £ (continued)
Items Comprising the VD Education HBM Scale Dimensions
14. Encouraging my fiiends who are sexually active to have regular VD checkups a
minimum of four times a year.

Source; Simon, K. & Das, A. (1984). An application of the Health Belief Model toward
educational diagnosis for VD education. Health Education Ouarterlv. 415-416.
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